Opendata, web and dolomites

RheumArth SIGNED

New drug for the treatment of rheumatoid arthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RheumArth project word cloud

Explore the words cloud of the RheumArth project. It provides you a very rough idea of what is the project "RheumArth" about.

proof    self    human    causing    permanent    first    disorder    time    annual    medium    showing    company    candidate    30    modulating    clinical    poc    proportion    variety    tissues    healthy    iia    ensuing    amounting    validate    decreased    rheumatoid    chemically    damage    small    severe    proved    disease    incidence    synthesized    inflammation    molecule    efficacy    trail    1st    million    arthritis    effectiveness    safety    instrument    anti    people    sme    patients    patient    preliminary    therapies    mobilizing    generation    trials    compliance    ra    life    area    treatments    autoimmune    45billion    provider    expectancy    threatening    alone    strategic    renders    positioning    position    drug    immune    utmost    quality    combination    joints    inflammatory    ap1189    context    mechanisms    surrounding    indication    drugs    activation    volunteers    unprecedent    disability    tolerance    validation    innovation    foothold    synact    treatment    therapeutic    supporting    foreseen    chronic    profile    market    acute    prepare   

Project "RheumArth" data sheet

The following table provides information about the project.

Coordinator
SYNACT PHARMA APS 

Organization address
address: DRONNINGGARDS ALLE 136
city: HOLTE
postcode: 2840
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.synactpharma.com/sv/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNACT PHARMA APS DK (HOLTE) coordinator 50˙000.00

Map

 Project objective

Rheumatoid arthritis (RA) is a chronic autoimmune disorder causing inflammation and permanent damage in joints and surrounding tissues - leading to severe disability, decreased quality of life, and reduced life expectancy. The disease affects more than 6 million people with annual costs amounting to €45billion in the Europe (EU) alone. There is a wide range of drug therapies for RA, mobilizing a variety of anti-inflammatory and immune modulating effects. However, a significant proportion (30%) of the patients do not respond to current treatments, efficacy is often reduced over time and the incidence of side effects is high and can be severe and life threatening. AP1189 is new chemically-synthesized small molecule drug for the treatment of Rheumatoid arthritis (RA). Through specific activation of the patients’ self-anti-inflammatory mechanisms, our first drug candidate renders unprecedent combination of safety, effectiveness and patient compliance, without the side effects associated with current therapies. The clinical validation of our drug for RA - 1st indication (foreseen for the Innovation Project) - will not only open a large market within this therapeutic area, as it will allow Synact to set a market foothold in the chronic inflammatory disease market, supporting the company´s medium term strategic positioning as an unique provider of a new generation of anti-inflammatory drugs. AP1189 clinical validation is on-going with current Phase I clinical trials showing promising preliminary results – safety and tolerance was proved in healthy human volunteers. Next step in the development will be a Phase IIa Proof-Of-Concept (POC) trail to validate our drug´s efficacy profile in RA patients. In this context, the present Phase 1 will be of utmost importance to validate AP1189´s market position and potential in RA and prepare the large clinical validation aimed for in the ensuing SME Instrument Phase II project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RHEUMARTH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RHEUMARTH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More